Dose Escalation of Lenvatinib effective for Differentiated Thyroid Carcinoma, study finds
Written By : Dr.Niharika Harsha B
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-07-06 14:00 GMT | Update On 2022-07-06 14:01 GMT
Advertisement
Dose escalation of Lenvatinib has successfully been used to treat Differentiated Thyroid carcinoma (DTC) based on a study that was published in the journal, Endocrine.
Dose Escalation (DE) is a process where the dose of the drug is increased to reach the anti-tumor effect after dose reduction. This is done when there are few drugs available for treatment and when treatment is continued with one agent. Lenvatinib is started at a standard dose for the treatment of thyroid cancer and by balancing between efficacy and the adverse events, dose reduction or dose interruption is done.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.